Keywords: reaction, avandia, warnings, stronger, among, internists, endocrinologists
Reaction to Avandia warnings stronger among internists than endocrinologists
Article | 23 July 2007
Since the May New England Journal of Medicine report that users of GlaxoSmithKline's diabetes drug Avandia (rosiglitazone maleate) are 43% more ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
